Embolism

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 13, 2024

BURLINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided a business update. 

Key Points: 
  • Product revenues were $6.1 million, and cost of product revenues were $1.8 million for the fourth quarter of 2023.
  • Research and development expenses were $3.3 million for the fourth quarter of 2023, compared to $2.3 million for the fourth quarter of 2022.
  • Selling, general and administrative expenses were $16.2 million for the fourth quarter of 2023, compared to $7.2 million for the fourth quarter of 2022.
  • scPharmaceuticals reported a net loss of $13.8 million for the fourth quarter of 2023, compared to $9.2 million for the fourth quarter of 2022.

AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE

Retrieved on: 
Thursday, April 4, 2024

The expanded FDA indication allows for the utilization of the AlphaVac F1885 System for the treatment of PE, which broadens the applicability of the AlphaVac F1885 System in the non-surgical removal of thrombi or emboli from the venous vasculature.

Key Points: 
  • The expanded FDA indication allows for the utilization of the AlphaVac F1885 System for the treatment of PE, which broadens the applicability of the AlphaVac F1885 System in the non-surgical removal of thrombi or emboli from the venous vasculature.
  • The indication expands treatment options for patients with PE, reducing thrombus burden and improving right ventricular function.
  • “The addition of the AlphaVac System in the mechanical thrombectomy world is a critical step forward in the treatment of PE patients,” said Dr. Keeling.
  • “The 510(k) clearance of the AlphaVac System represents an important milestone towards the treatment of PE,” said Mona Ranade, MD, Assistant Professor, Interventional Radiology, at the David Geffen School of Medicine at UCLA.

Avicenna.AI secures FDA clearance for two healthcare AI solutions

Retrieved on: 
Tuesday, March 26, 2024

La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products. Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.

Key Points: 
  • La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products.
  • Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.
  • CINA-iPE and CINA-ASPECTS are the latest tools from Avicenna.AI to secure FDA clearance, joining its AI solutions for medical emergencies, including automatic detection of intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE) from CT-scan imaging.
  • "The clearance of CINA-iPE and CINA-ASPECTS marks a significant milestone in our mission to strive for excellence in advancing patient care.

Avicenna.AI secures FDA clearance for two healthcare AI solutions

Retrieved on: 
Tuesday, March 26, 2024

La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products. Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.

Key Points: 
  • La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products.
  • Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.
  • CINA-iPE and CINA-ASPECTS are the latest tools from Avicenna.AI to secure FDA clearance, joining its AI solutions for medical emergencies, including automatic detection of intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE) from CT-scan imaging.
  • "The clearance of CINA-iPE and CINA-ASPECTS marks a significant milestone in our mission to strive for excellence in advancing patient care.

Jelqing: the latest in a long history of attempts to enlarge the male member

Retrieved on: 
Thursday, February 15, 2024

Posts advise that stretching a semi-erect penis could add up to an inch in length and girth by exploiting the body’s repair mechanisms.

Key Points: 
  • Posts advise that stretching a semi-erect penis could add up to an inch in length and girth by exploiting the body’s repair mechanisms.
  • Jelqing is just the latest in a long line of dubious penis enlargement techniques stretching (sorry) back millennia.
  • The ancient Greek method of lengthening the foreskin with a kynodesme (dog leash) seems positively mild compared with ancient Indian methods.
  • Penis pumps are also used for erectile dysfunction, but unlike some online claims, they don’t lengthen the penis.

Surgical interventions

  • Fillers are increasing in popularity, particularly hyaluronic acid (HA) injections.
  • HA is popular because it is doesn’t generate an immune response.
  • Surgery to cut the suspensory ligament anchoring the penis is the most widely accepted surgical elongation method.
  • A recent review concluded that evidence for supporting surgical procedures for penis enlargement is weak and the complications are under-reported.

Not needed, in most cases

  • A micropenis, usually diagnosed at birth, is where the penis is 2.5 standard deviations less than the average stretched penis length (2.3 to 2.5cm depending on ethnicity).
  • It is typically caused by a deficiency or imbalance of hormones such as testosterone or human chorionic gonadotropin (hCG), or genetics.
  • The female vagina is on average 2.5 to 3.8 inches deep, but lengthens during sexual arousal to accommodate a penis longer than this.
  • The female genitalia have multiple erogenous structures that can result in orgasm, so penile length isn’t the key characteristic.

A closer look at jelqing

  • The top two consist of numerous spaces that are surrounded by smooth muscle, which keeps most blood out of the spaces.
  • During an erection, the muscles relax allowing blood to flow in, filling these spaces, and enlarging penile volume.
  • While the theory sounds good, smooth muscle cells in the penis don’t respond in the same way skeletal muscle does.
  • If jelqing, or any other trend, was really that effective, we would have seen evidence of it in medical journals, and the sale of extra-large underwear would be making the headlines.


Adam Taylor does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee

Retrieved on: 
Monday, January 22, 2024

Surmodics’ Pounce Thrombectomy devices are intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature.

Key Points: 
  • Surmodics’ Pounce Thrombectomy devices are intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature.
  • The new Pounce LP Thrombectomy System is indicated for use in vessels ranging from 2 mm to 4 mm in diameter, sizes typical of vessels found below the knee.
  • The Pounce LP System complements the original Pounce Thrombectomy System, introduced in 2021, which is indicated for use in vessels 3.5 mm to 6 mm in diameter.
  • The Pounce LP System’s ability to capture and remove these unexpected emboli adds yet more value to this device for BTK revascularization.”

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Retrieved on: 
Thursday, January 4, 2024

BURLINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced preliminary unaudited fourth quarter 2023 net FUROSCIX revenue in a range of $5.9 million to $6.1 million, representing sequential growth of 55% to 61% over $3.8 million net FUROSCIX revenue reported for the third quarter of 2023.

Key Points: 
  • For the full year 2023, the Company anticipates net revenue to be in a range of $13.4 million to $13.6 million.
  • The gross-to-net discount decreased to approximately 18% from launch through the end of Q4 versus 21% from launch through the end of Q3.
  • Inventory levels at the end of Q4 2023 were consistent with levels at the end of Q3 2023.
  • scPharmaceuticals will report its final and complete fourth quarter and full-year 2023 financial results in March.

Providence Mission Hospital Receives 2024 Healthgrades Cardiac Surgery Excellence Award for Third Consecutive Year

Retrieved on: 
Thursday, January 4, 2024

The Providence Mission Hospital Heart and Vascular Institute has been awarded the 2024 Healthgrades Cardiac Surgery Excellence Award for the third consecutive year, and it is among the top 10% of hospitals in the nation for cardiac surgery.

Key Points: 
  • The Providence Mission Hospital Heart and Vascular Institute has been awarded the 2024 Healthgrades Cardiac Surgery Excellence Award for the third consecutive year, and it is among the top 10% of hospitals in the nation for cardiac surgery.
  • The hospital is also a Five-Star recipient for Coronary Bypass Surgery for the second year in a row and a Five-Star recipient for the treatment of pulmonary embolisms.
  • The Healthgrades Cardiac Surgery Excellence Award highlights hospitals that deliver superior patient outcomes in heart bypass and heart valve surgery.
  • “The cardiac surgery team at Mission Hospital is comprised of the most extraordinary clinicians – it is truly an honor to serve alongside them to care for our South Orange County neighbors,” said Dr. Sevak Darbinian, chief of cardiothoracic surgery at Providence Mission Hospital since 2008.

Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised